What's new

Human medicines European public assessment report (EPAR): Beqvez (previously Durveqtix), fidanacogene elaparvovec, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Beqvez (previously Durveqtix), fidanacogene elaparvovec, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised

May 20, 2025 - 12:15
 0
Human medicines European public assessment report (EPAR): Beqvez (previously Durveqtix), fidanacogene elaparvovec, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Beqvez (previously Durveqtix), fidanacogene elaparvovec, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised
Read More

Tags:

Previous Article

Stars align for CRISPR Tx, Sirius as pair pens siRNA collab with a focus on thro...

Next Article

Human medicines European public assessment report (EPAR): Zavicefta, ceftazidime...

Related Posts

Appendix 1: Acceptable intakes established for N-nitros...

May 15, 2025  0

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

May 15, 2025  0

European shortages monitoring platform (ESMP): updates and question and answer (Q&A) clinic for marketing authorisation holders (MAHs), Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 June 2025, 10:30 (CEST) to 24 June 2025, 12:00 (CEST)

European shortages monitoring platform (ESMP): updates ...

May 14, 2025  0